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Summary
CK2 is a very pleiotropic protein kinase whose high
constitutive activity is suspected to cooperate to
neoplasia. Here, the crystal structure of the com-
plexes between CK2 and three selective tetrabromo-
benzimidazole derivatives inhibiting CK2 with Ki val-
ues between 40 and 400 nM are presented. The ligands
bind to the CK2 active site in a different way with re-
spect to the parent compound TBB. They enter more
deeply into the cavity, establishing halogen bonds
with thebackboneofGlu114 andVal116 in thehinge re-
gion. A detailed analysis of the interactions highlights
a major role of the hydrophobic effect in establishing
the rank of potency within this class of inhibitors and
shows that polar interactions are responsible for the
different orientation of themolecules in the active site.
Introduction
Protein kinases, which catalyze the transfer of the g
phosphate of ATP (and, seldom, GTP as well) to serine,
threonine, and tyrosine residues of protein substrates,
play a central role in controlling nearly all cellular func-
tions, with special reference to signal transduction. They
makeuponeof the largest families ofenzymes,withmore
than 500 members encoded by the human genome [1]
and often unscheduled and/or constitutive activation of
individual protein kinases underlies pathologies [2]. Con-
sequently, the development of efficient and selective in-
hibitors of protein kinases represents a powerful tool for
unraveling the functional implicationof individualkinases
and, in some cases, it may also provide leads with phar-
macological potential. Indeed, protein kinases now rep-
*Correspondence: roberto.battistutta@unipd.it (R.B.), pinna@civ.
bio.unipd.it (L.A.P.)resent the second most important target for therapeutic
agents [3, 4]. Several protein kinase inhibitors are already
in advanced clinical trials, or even in clinical practice, to
cure tumors and other diseases [3, 5, 6]. Interestingly,
most of these inhibitors are competitive with respect to
ATP, a circumstance that could sound surprising, given
that the ATP binding site is highly conserved in all mem-
bers of the protein kinase family. The explanation for
such an apparent incongruence was provided by the
solution of the crystal structure of complexes between
protein kinases and a number of ATP site-directed inhib-
itors (reviewed in [7]), revealing that these do not exactly
mimic the mode of binding of ATP but rather occupy a re-
gion adjacent to and partially overlapping the actual ATP
binding site. This region, mainly composed of the hinge
segment connecting the upper and lower lobes of the
kinase and two hydrophobic pockets, displays sufficient
variability across protein kinases to be exploited to har-
bor specific ligands [8]. In this respect, the solution of the
crystal structure of complexes between kinases and ATP
site-directed ligands represents the most powerful tool
for scrutinizing the mode and structural consequences
of binding of these compounds and for the design of
more potent and selective inhibitors ([7, 9–11] and refer-
ences therein).
Specific inhibitors are especially needed in the case of
constitutively active protein kinases, which, unlike most
other members of the family, are not activated in re-
sponse to specific stimuli—nor do they exist within the
cell as inactive and active forms, generally distinguish-
able for different degrees of phosphorylation. Therefore,
alternative tools such as physiological agonists/antago-
nists, phosphospecific antibodies, and transfection with
constitutively active mutants (where the phosphoresi-
due responsible for activation has been mimicked by
a carboxylic side chain) are not applicable to dissecting
the cellular functions mediated by constitutively active
kinases. Highly selective, cell-permeable inhibitors re-
main among the few applicable strategies for gaining in-
formation about the biological roles of constitutively ac-
tive protein kinases.
A striking example of constitutively active protein ki-
nase is provided by CK2, an acronym derived from the
misnomer ‘‘casein kinase-2.’’ CK2 is the most pleiotro-
pic Ser/Thr kinase known to date, with a growing list of
more than 300 protein substrates, many of which are im-
plicated in a variety of important cellular functions, with
special reference to signal transduction, gene expres-
sion, and DNA synthesis and repair [12]. CK2 catalytic
subunits (a and a0) are constitutively active either alone
or in combination with the regulatory b subunit to give
a heterotetrameric holoenzyme composed by two cata-
lytic subunits held together by a b2 dimer, functioning as
a docking and/or targeting element rather than as a ca-
nonical regulatory subunit [13–16]. It has been sug-
gested that constitutive activity of CK2 may reflect its
extraordinary pleiotropy, which would be hardly com-
patible with the necessity of keeping quiescent CK2 ac-
tivity within a living cell at any moment [13]. On the other
hand, such a lack of downregulatory mechanisms may
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by an increasing number of observations. CK2 activity is
invariably elevated in many different kinds of tumors (re-
viewed in [17]), and overexpression of its catalytic sub-
units is causative of neoplastic growth in animal and cel-
lular models presenting alterations in the expression of
cellular oncogenes or tumor suppressor genes [18–21].
Also remarkable in this context is the increasing evi-
dence that CK2 plays a global antiapoptotic role [22],
which could account for its implication in those kinds
of tumors, exemplified by prostate carcinoma, whose
key feature is deregulation of programmed cell death.
An added value of CK2 inhibitors could also be their ex-
ploitation in infectious diseases, in that many viruses de-
pend on host cell CK2 for the phosphorylation of pro-
teins that are essential to their life cycle [17].
Not surprisingly, therefore, an increasing number of
recent reports deal with pharmacological inhibition of
CK2 by a variety of compounds. These include flavo-
noids, notably apigenin [23] (whose selectivity, however,
is quite modest [24]), emodin [25], and other condensed
polyphenolic compounds [26], the indoloquinazolin de-
rivative IQA [24, 27], and a variety of halogenated benz-
imidazole/triazole compounds developed from the orig-
inal molecule DRB [28, 29]. The one most successfully
used at present is 4,5,6,7-tetrabromo-1-benzotriazole
(TBB), a very selective, cell-permeable CK2 inhibitor
[30] that is proving useful in documenting the implication
of CK2 in a variety of cell functions (notably apoptosis
[31], repair of chromosomal DNA single-strand breaks
[32], functionality of the pleiotropic cochaperone CDC-
37 [33], and upregulation of the Akt signaling pathway
[34]) and in identifying new protein targets of CK2 (re-
viewed in [35]). Recently, the inhibitory properties of
TBB have been further improved by the generation of a
number of tetrabromo-benzimidazole derivatives, some
of which display the same selectivity and cell permeabil-
ity of the parent compound but a higher inhibitory effi-
cacy, with Ki values in the low nanomolar range [36].
Here we describe the crystal structure of three of these
compounds, bound to the active site of the catalytic sub-
unit of CK2. The data collected, in conjunction with those
of the TBB complex and of the apoenzyme [37], allow
a detailed structure-activity relationship study of this
class of CK2 inhibitors and provide valuable hints for
the design of more selective and potent inhibitors.
Results and Discussion
TBB is a cell-permeable, selective, and fairly potent CK2
inhibitor that has been successfully used to validate the
involvement of this pleiotropic kinase in different cellular
events (see Introduction). The shape and the reduced di-
mension of the CK2 ATP binding site were proposed to
play a key role for determining the selectivity of this in-
hibitor [37]. Accordingly, mutagenesis studies have
highlighted the relevance of the unique residues Ile/
Val66 and Ile174, whose replacement by alanine de-
creases susceptibility of CK2 to TBB inhibition. Recall
in this respect that the hydrophobic moiety of protein ki-
nase ATP binding sites is more variable than the polar
one, which is highly conserved. Selectivity therefore is
better ensured by interactions with the hydrophobic re-
gion [38, 39].Several TBB derivatives have been recently synthe-
sized and tested on CK2 in the attempt to improve the
inhibitory properties [36]. For those with the lowest in-
hibitory constants, crystallization trials have been set
up in complex with the Zea mays CK2 a-catalytic sub-
unit, whose active core is nearly identical to that of its
human homolog. Three of these, namely K25 (also
termed DMAT; see [40]), K44 (whose synthesis is de-
scribed here), and K37 [36], have produced crystals dif-
fracting to a reasonable resolution (see Table S1 for data
collection statistics). Note that K25 displays a Ki value
for CK2 of 40 nM, the lowest reported in the literature
for a CK2 inhibitor. Its selectivity and cell permeability
are similar to those of TBB, rendering K25/DMAT the
first choice CK2 inhibitor for in-cell studies.
Synthesis of K44 (N1,N2-Ethylene-2-Methylamino-
4,5,6,7-Tetrabromo-Benzimidazole)
Compound 2 (Scheme S1) was obtained by amination of
2,4,5,6,7-pentabromobenzimidazole1 [41]with 2-(methyl-
amino)ethanol. The reaction of the hydroxyalkyl com-
pound 2 with thionyl chloride gave a chloroalkyl deriva-
tive, which was cyclized to compound 3 upon heating
in ethanolic solution in the presence of DBU (1,8-diazabi-
cyclo[5,4,0]undec-7-ene) as base. Attempts to isolate
the chloroalkyl intermediate were unsuccessful, due to
partial cyclization during crystallization. The detailed
synthesis procedures are described under Experimental
Procedures. The chemical structures of newly obtained
products were confirmed by elemental analyses, 1H
NMR, and mass spectroscopy.
Structural Effects on CK2 upon TBB-Derivatives
Binding
Like TBB, the three new derivatives are ATP-competitive
and, as expected, they occupy the ATP binding region
between the N-terminal and the C-terminal lobes of the
enzyme. The overall three-dimensional structure of the
enzyme is essentially conserved, with only minor changes
in some flexible residues facing the binding pocket. The
major variations are seen in the conformation of the Gly-
rich loop and of the hinge region, as well as in the side
chains of His160 and Met163. In the K44 complex, a rear-
rangement in the electrostatic interactions between the
charged Lys68, Glu81, and Asp175 is observed (as dis-
cussed in detail below). As seen for other CK2 com-
plexes [6, 11, 24, 37, 42, 43], the flexible loop 102–108
adopts an extended conformation that corresponds to
a ‘‘longer’’ b unit cell axis of around 59-61 A˚ and a b angle
of approximately 103–104º (instead of values of approx-
imately 52 A˚ and 99º, respectively, corresponding to the
loop in a bent conformation; see also Experimental Pro-
cedures).
In the CK2 complexes with Emodin and TBB, the
His160 side chain was displaced from its original posi-
tion, thus entrapping the ligand inside the binding
pocket. The flexibility of this side chain is confirmed by
the fact that in the CK2/K44 complex it is clearly visible
in a double conformation, one pointing to the solvent
and the other to the binding site; this latter conformation
is similar to that of the Emodin complex.
Apart from Emodin, in all other CK2-inhibitor com-
plexes a conserved water molecule was always found
hydrogen bonded to the Trp176 backbone nitrogen
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molecule is also present in all three of the new structures
here described.
Polar Interactions between CK2 and Inhibitors
In the binding cavity, K25, K44, and K37 lie essentially in
the same plane of TBB but penetrate deeper, reaching
the hinge region. Each derivative makes two direct inter-
actions with the same elements of this region (i.e., the
backbone carbonyls of Glu114 and Val116) (Figure 1);
these residues are pushed back with respect to their po-
sition in the TBB bound complex and in the apoenzyme.
Note that these are the same residues that interact with
the adenine moiety of ATP when bound to the active site
[44]. In all cases, the inhibitors interact with the hinge re-
gion through two bromine atoms, at a distance between
2.9 and 3.4 A˚ from the carbonyl oxygen atoms. The na-
ture of this interaction has been already discussed in
the case of CDK2 protein kinase in complex with TBB
[45]. It consists of a weak noncovalent interaction shown
to occur between carbon-bonded halogens (Cl, Br, or I)
and electronegative atoms (notably O and N), called
a halogen bond, with a strong directional preference,
mainly due to electrostatic effects that arise from an an-
isotropic electronic distribution of the halogen atoms
[46, 47]. In our complexes, the distances between the
bromine and the oxygen atoms (between 2.9 and 3.4
A˚, less than or equal to the sum of the van der Waals radii
of oxygen, 1.52 A˚, and bromine, 1.85 A˚) and the direc-
tionality of the interactions (angle C—Br $$$$$ O close
to the optimal value of 165º) are consistent with an at-
tractive interaction. In general, the stabilizing effect of
a halogen bond is estimated between about half to
slightly more than that of hydrogen bonds, depending
on the geometry of the interaction. For K44, two addi-
tional halogen bonds are established by Br6 and Br7,
with a water molecule and the Asp175 side chain, re-
spectively (see Figure 2A), totaling four halogen bonds,
one for each bromine atom.
Figure 1. Superpositions of K25
Superpositions of K25 with TBB (A) and with K44 (B); the two con-
formations A and B of K37 are also shown (C). The TBB position is
indicated as reference. The interactions with Glu114 and Val116 of
the hinge region of CK2 (halogen bonds) are indicated by dashed
lines. Note the similar orientation of K37A with K44 and of K37B
with K25.As in the case of the TBB parent molecule, there are
no direct hydrogen bonds between any of the TBB-
derivatives atoms and the protein, and only a few with
water molecules, as illustrated in Figure 2. A further po-
lar interaction is established by a nitrogen atom of K25
that is at a van der Waals distance to a chlorine ion (Fig-
ure 2B), in such a way that a polar electrostatic interac-
tion can be hypothesized between the two. A chlorine
ion is evident also in the K44 structure, where however
it does not interact with the inhibitor.
Overall, taking into account only the polar interactions
just described, it is difficult to explain the differences in
the experimental values of IC50 and Ki. For instance, al-
though K44 is the inhibitor with the highest number of po-
lar interactions with the protein, nevertheless it has an in-
hibitory potency lower than that of K25, which makes
fewer polar contacts with CK2. Furthermore, looking at
only these interactions it is not clear why TBB is a better
inhibitor for CK2 than for the protein kinase CDK2, with
which it is able to form four halogen bonds [45].
Apolar Interactions between CK2 and Inhibitors
In the attempt to correlate the contribution of the apolar
interactions (i.e., van der Waals interactions and hydro-
phobic effect) to the binding of different inhibitors, two
types of analysis were performed, based on (1) the num-
ber of van der Waals contacts between CK2 and the in-
hibitors (with two cutoffs of 3.7 and 3.9 A˚) and (2) the
amounts of the accessible surface area buried (DASA)
upon binding of the inhibitors to CK2. Details about
both analyses performed are described in the Experi-
mental Procedures section and the main results are
shown in Table 1, together with the IC50 and Ki values.
As in the case of the polar interactions, the number of the
van der Waals contacts seems not to correlate with the
inhibitory potency (Table 1). For instance, K25 makes
the lowest number of contacts even though it presents
the lowest Ki. In contrast, a reasonable correspondence
is observed between the inhibitory potencies and the
Figure 2. Polar Interactions
Polar interactions between CK2 and K44 (A), K25 (B), and K37 in
conformation A (C) and conformation B (D). Only distances (in A˚) be-
tween the inhibitors and the protein atoms are indicated. Note the
different location of the chlorine ions in panel A (Cl2 far from the in-
hibitor K44) and B (Cl2 ion paired with Lys68 can directly interact
with K25). The parent compound TBB (not shown) does not make
any direct polar interaction with CK2 residues of the active site.
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upon Ligand Binding
vdW DASA (A˚2)
%3.7 A˚ %3.9 A˚ DASAin DASAprot DASAtot IC50 Ki
TBB-CDK2 9 19 342.2 192.9 535.1 15.6 —
TBB-CK2 13 19 375.4 206.0 581.4 0.50 0.40
K44 12 24 379.5 214.6 594.1 0.74 0.10
K37_Aver 15a/18b 28a/31b 397.1 231.2 628.3 0.25 0.07
K25 9 22 413.1 259.1 672.2 0.14 0.04
DASAin, DASA inhibitor; DASAprot, DASA protein; DASAtot: DASA total, sum of DASA inhibitor and DASA protein; K37_Aver: values averaged
between the two conformations.
a Values relative to conformation A of K37.
b Values relative to conformation B of K37.total accessible surface areas buried upon ligand bind-
ing to CK2 (DASAtot values in Table 1). Note that these
areas are mostly apolar on both sides, supporting the as-
sumption that the extent of the surface areas no longer
accessible to the solvent is proportional to the strength
of the hydrophobic interaction. This contribution arises
from the entropic gain due to the transfer of water mol-
ecules from the hydrophobic surfaces of the CK2 bind-
ing site and the inhibitors to the bulk solution. From
the plot of the logarithmic values of the Ki and IC50 ver-
sus the DASAs, a linear relationship between these
parameters could be obtained (see Figure 3).
Although the hydrophobic effect alone can explain the
differences in the potencies within this class of inhibi-
tors, a fundamental contribution to the overall energetic
of binding must be attributed also to the van der Waals
interactions, as demonstrated by the importance of the
presence in the inhibitors of bromine atoms instead of
other halogens with different van der Waals radii [37].
Relative Influence of the Hydrophobic Effect and
Polar Interactions in the Binding of TBB-Derivatives
to CK2
The analysis reported in the preceding sections supports
the notion that the hydrophobic effect is principally re-
sponsible for the differences in the inhibitory potency
of TBB and its derivatives against CK2. For instance, de-
Figure 3. Correlation between Log(Ki) and Values of DASAtot for
the Different Inhibitors
For TBB-CDK2, the log(IC50) is reported, as in Table 1.spite K44 shows a more extensive network of polar inter-
actions, and it has an inhibitory constant Ki higher than
that of K25, in accordance with the lower DASA of bind-
ing, 594 versus 672 A˚ [2].
The polar interactions, however, appear to play a role
in orienting the ligands inside the active site. Note that,
although the positions of the three molecules inside
the ATP binding pocket are similar, the respective orien-
tations are quite different, as highlighted by the bro-
mines that interact with Glu114 and Val166: these are
Br5 and Br6 in the case of K25, and Br4 and Br5 in the
case of K44 (Figures 1, 2A, and 2B). Concerning K37,
two orientations have been found in the crystal struc-
ture; Br4 and Br5 interact with the hinge region in one
case (conformation A), and Br5 and Br6 in the other
case (conformation B), with an occupancy of 60% and
40%, respectively (Figures 1, 2C, and 2D). Conformation
A of K37 resembles that of K44 (Figures 2A and 2C) and
conformation B resembles that of K25 (Figures 2B and
2D). These dissimilar orientations of the inhibitors can
be ascribed mainly to small but relevant differences in
the dimensions, electronic configurations, and polariz-
ability of these small ligands.
The crystal structures of the K25 and K44 complexes
disclose the presence of chlorine ions inside the binding
site in a way that causes a rearrangement in the local
electrostatic field of the polar moiety of the cavity. In
the case of K44, the presence of a chlorine ion contrib-
utes to the displacement of two residues conserved
among protein kinases and crucial for the activity of
the enzyme, Lys68 and Asp175, now at an ion-pair dis-
tance (Figure 4). These residues are now part of a com-
plex network of polar interactions, involving the chlorine
ion, several water molecules and two bromine atoms
(Br6 and Br7) and a nitrogen of the inhibitor (Figure 2A).
In the case of K25, a chlorine ion is close to an aromatic
nitrogen of K25 and is stabilized by the amine function of
the Lys68 side chain and by the amide nitrogen of the
Asp175 backbone (Figure 2B).
From a superimposition of the crystal structures, it
turns out that TBB binds to protein kinase CDK2 in a
way very similar to that of K25 bound to CK2, with the
same bromine atoms interacting with corresponding res-
idues of the hinge region (Glu81 and Leu83 for CDK2,
Glu114 and Val116 for CK2, respectively). The different
modes of interaction of TBB with the active sites of
CK2 and CDK2 can be attributed to a variation in the
shape and dimension of the two cavities, with special
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contribution to the binding energy is due to the hydro-
phobic effect. This effect is higher in the case of CK2,
as indicated by the different DASA: 535 A˚2 for CDK2
and 581 A˚2 for CK2. This may be due, at least partially,
to the replacement of two bulky side chains of CK2, those
of Ile/Val66 and of Ile174, by alanines in CDK2. Note that
the amino acids with higher values of DASA upon ligand
binding to CK2 are Val45, Val53, Ile66, Met163, Ile174,
and Asp175 (Table 2 and Figure 5). Three of these
(Ile66, Met163, and Ile174) are unique for CK2 and are
those that presumably contribute to a greater extend to
the diversity of the ATP binding site, which is smaller
than in the majority of the other kinases as indicated by
the unusually low sensitivity of CK2 to staurosporine
and by its selectivity for TBB and related compounds.
The fact that Asp175 also shows a remarkable variation
in the value of DASA is in accordance with its function
in coordination of a Mg2+ ion when an ATP molecule is
bound.
Like the parent compound TBB, the three derivatives
dealt with in the present study inhibit CK2 more potently
than CDK2, as shown by their IC50 values (Table 3). Note,
however, that the ratio between IC50 values and the two
kinases denotes an improvement of their relative effi-
cacy toward CDK2, especially remarkable in the case
of K37. Again, the small size of the CK2 active site com-
pared to that of CDK2 seems to be important in this re-
spect; overall, the decrease in the IC50(CDK2/CK2) ratios
can be explained with the increased dimension of the
derivatives compared to TBB, suggesting that they can
better interact with the larger cavity of CDK2. On the
other hand, the trends of the IC50 ratios and CDK2 IC50
values are difficult to completely rationalize in absence
of the corresponding experimental crystal structures.
Although the effect of mutating Met163 could not be
assessed because the M163G mutant proved catalyti-
cally inactive [35], the importance of Ile66 and Ile174
was experimentally validated by mutational studies by
which Val66 (the homolog of Ile66 in human CK2) and
Ile174 were individually or collectively mutated to one
or more alanines. These mutations were detrimental to
the inhibitory potency of a variety of compounds, includ-
Figure 4. K44 Interactions
Main interactions (dashed lines) of K44 in the active site of CK2 are
shown. Note the four halogen bonds between K44 bromine atoms
and the protein and the different conformations of Lys68 and Glu81
(dark gray) compared to that in the K25 complex (light gray). This
rearrangement is favored by the presence of a negative chlorine
ion near the positive amine function of Lys68. The positions of
two water molecules part of the network of interactions are indi-
cated by small spheres.ing TBB and K25 (DMAT), but increased the inhibitory ef-
ficiency of staurosporine [26].
In general, as also exemplified in Table 3 by TBB and
K25, each inhibitor responds in a different manner to
the individual mutation of either V66 or I174, and the dou-
ble mutation tends to display an additive or less than ad-
ditive effect, reflecting subtle differences in binding and
suggesting that the inhibitor adopts a different confor-
mation in the mutated site in order to partially compen-
sate the lost interactions with new ones (note in this re-
spect that in the case of TBB the double mutation is
less effective than that of V66 alone). In this context,
K44 represents a remarkable exception in that (1) it is
equally susceptible to either the V66 or the I174 muta-
tions, and (2) the efficacy of the double mutation is
much more than additive, giving rise to a CK2 form which
is practically insensitive to the inhibitor. In this respect
the combined usage of K44 and the CK2 double mutant
V66A, I174A appears as the first choice strategy to probe
the real implication of CK2 in a cellular function when-
ever one wants to disprove the suspect that the inhibitor
operates through alternative targets, other than CK2.
Significance
The main lesson to be drawn from the data presented
is that closely related compounds sharing an identical
scaffold can bind to the active site of the same protein
kinase in substantially different manners as a conse-
quence of subtle structural alterations. In the case
considered (protein kinase CK2 and TBB related inhib-
itors), the 10-fold range variation inKi (40–400 nM) can-
not be correlated in a straightforward manner to the
number and type of polar interactions observed; these
interactions do, however, play an important role in the
orientation of each individual ligand inside the bind-
ing pocket. For this class of ligands, the extent of the
hydrophobic interactions (mediated by the common
tetrabromo-benzimidazole scaffold) is ultimately re-
sponsible for their rank in potency. Two important cor-
ollaries are, first, that the features of this class of li-
gands are different from what is generally observed
with other kinase inhibitors (whose binding potency
is often increased mainly because of an improvement
in the number or quality of polar interactions, notably
hydrogen bonds) and, second, that subtle differences
such as those outlined here are hardly predictable by
modeling, which makes the experimental approach
the only reliable tool for their elucidation. The struc-
tural information provided here can be applied to
Table 2. Residues with the Higher Accessible Surface Areas
Differences (DASA in A˚2) upon Ligand Binding
DASA (CK2) TBB K25 K44 K37_A K37_B DASAAver
Val45 25.0 18.8 33.7 24.6 18.5 24.1
Val53 27.8 29.1 21.9 26.9 30.3 27.2
Ile66 18.5 27.3 29.2 25.5 25.4 25.2
Met163 14.0 29.2 30.6 32.0 27.9 26.7
Ile174 27.4 41.5 26.8 32.7 34.6 32.6
Asp175 18.4 20.1 10.1 8.6 15.5 14.6
DASAAver: DASA averaged for the four inhibitors (for K37 two con-
formations are considered). See also Figure 5.
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(A) K44 (red), K25 (yellow), and TBB (blue). (B) K37 in the two conformations A (red) and B (yellow) and TBB (blue). Halogen bonds with two
residues (Glu114 and Val116) of the hinge region are indicated by blue dotted lines. (See also Table 2.)further improve the inhibitory potency of TBB deriva-
tives, without losing selectivity.
Experimental Procedures
Synthesis of K44 (N1,N2-Ethylene-2-Methylamino-4,5,6,7-
Tetrabromo-Benzimidazole)
AllchemicalsandsolventswerepurchasedfromSigma-Aldrich.Melt-
ing points were measured in open capillary tubes on a Gallenkamp-5
melting point apparatus. 1H NMR spectra (in ppm) were measured
with Varian Gemini 200 MHz and Varian UNITYplus spectrometers
at 298 K in dimethyl sulfoxide (DMSO)-d6 using tetramethylsilane as
internal standard.
Mass spectra (70 eV) were obtained with ADM-604 (Intectra) spec-
trometer. Elemental analyses (C, H, N) of new compounds were
within 60.4% of the respective theoretical values.
2-(2-Hydroxyethyl)Methylamino)-4,5,6,7-
Tetrabromobenzimidazole (2)
The mixture of 1 (4 g, 7.8 mmol) and 2-(methylamino)ethanol (8 ml,
100 mmol) in n-propanol (35 ml) was stirred and refluxed for 24 hr.Next, water (20 ml) was added and the solution was brought to pH
5 with acetic acid. The formed precipitate was filtered, washed
thoroughly with water and dried in vacuum (2.35 g, 59%). The chro-
matographic pure compound was used for the further step without
crystallization. The sample for analytical and enzymatic investiga-
tions was crystallized from ethanol. M.p. 243-245ºC. 1H NMR: 3.18
(s, CH3), 3.64 (t, CH2) 4.95 (bs, OH), 11.4 (bs, NH-benzim.); MS: 509
(23), 507 (35), 505 (24), 478 (24), 476 (36), 474 (25), 467 (16), 465
(64), 463 (100), 461 (69), 459 (18).
N1,N2-Ethylene-2-Methylamino-4,5,6,7-Tetrabromobenzimidazole
(3) (4,5,6,7-tetrabromo-1-methyl-2,3-dihydro-1H-1,3a,8-triaza-
cyclopenta[a]indene)
The suspension of 2 (1.2 g, 2.35 mmol) in thionyl chloride (12 ml) was
stirred and refluxed for 1 hr. The pale yellow solution was evapo-
rated to dryness and then twice with ethanol (23 50 ml). To the res-
idue EtOH (45 ml) and DBU (1.5 ml, 10 mmol) was added and stirred
and refluxed for 2 hr. The reaction mixture was treated with water (20
ml) and left to crystallize. The white, chromatographically pure pre-
cipitate formed (0.81 g, 70%) was filtered and washed with water.
For analytical purposes the sample was crystallized from ethanol.
CK2 Complex Crystal Structures
1217M.p. > 300ºC. 1H NMR: 2.97 (s, CH3), 3.95 (t, CH2), 4.39 (t, CH2); MS:
492 (16), 490 (64), 488 (100), 486 (69), 484 (18).
CK2 and CK2 Mutants
For kinetic experiments human CK2a wild-type and mutants V66A
and V66A,I174A were expressed and purified as described previ-
ously [48]. CK2a mutants and IC50 values were obtained as previ-
ously reported [36].
CDK2/CyclinA Phosphorylation Assays
Human CDK2/cyclinA [45] was kindly provided by Prof. Jane Endi-
cott. Phosphorylation assays were carried out in the presence of in-
creasing amounts of each inhibitor tested in a final volume of 30 ml
containing 16 ml of buffer C (60 mM b-glycerophosphate, 25 mM
MOPS, 5 mM EGTA, 15 mM MgCl2, 30 mM 4-nitrophenyl phosphate,
1 mM dithiothreitol [DTT], 40 nM of affinity purified CDK2/cyclinA,
0.83 mg/ml of histone H1 (Sigma type III-S) and 0.0125 mM [33P-
ATP] (500-1000 cpm/pmol). After 10 min incubation at 30ºC the reac-
tion was stopped, spotting 25 ml onto Whatman P81 phosphocellu-
lose. The filter were washed three times in 0.5% phosphoric acid and
dried before counting.
Crystal Preparation and Data Collection
The recombinant CK2 a-subunit from Zea mays was expressed in
Escherichia coli, isolated and purified according to a previously de-
scribed method [37]. Crystals of the CK2 complexes with the three
inhibitors K44 (N1,N2-ethylene-2-methylamino-4,5,6,7-tetrabromo-
benzimidazole), K25 (4,5,6,7-tetrabromo-2-(dimethylamino) benz-
imidazole), and K37 (S-methyl-4,5,6,7-tetrabromo-benzimidazole)
were obtained by cocrystallization with the sitting drop vapor-diffu-
sion technique. The 8 mg/ml protein stock solution was preincu-
bated with a 100 mM inhibitor solution (100% DMSO) in the proper
amount to have an inhibitor-protein molar ratio of 3:1, and not to ex-
ceed a 5% DMSO concentration in the final protein solution.
Crystallization trails were performed by mixing a 2 ml drop of pre-
incubated stock solution with 4 ml of water and 2 ml of precipitant so-
lution (10%–20% PEG 4000, sodium acetate 0.2 M, Tris 0.1 M pH 8).
The drop was equilibrated against 500 ml of the same precipitant so-
lution (20% PEG 4000). Crystals grew in few days at 293 K.
For all the three inhibitors X-ray diffraction data were collected at
the X-ray diffraction beam-line of the ELETTRA synchrotron facility
on a Mar CCD detector, at a temperature of 100 K. Before mounting,
crystals were cryoprotected by a very rapid soaking in type B immer-
sion oil (Hampton Research). Statistics on data collection are reported
in Supplemental Table S1. Data were indexed with MOSFLM [49] and
then scaled with SCALA from the CCP4 software package [50].
Structure Determination and Refinement
All three enzyme-inhibitor complexes crystallize in the space group
C2, with one molecule in the asymmetric unit. All maize CK2a crystal
structures known so far belong to this space group, with the excep-
tion of the complex with TBB that crystallized in the space group P1
[37]. As discussed in ref [43], the ‘‘stretched’’ b cell parameters and
the b angles (Table S1) are compatible with the extended conforma-
tions of the loop 102–108, and indeed this is what is found in the final
models. The fact that now a silicon oil was used as cryoprotectant
Table 3. IC50 Values of TBB and TBB Derivatives Relative to CK2,
Val66Ala, and/or Ile174Ala Mutants and CDK2/Cyclin A
Inhibitor
IC50 values (mM) Ratio IC50
CK2 V66A I174A V66A,I174A CDK2 (CDK2/CK2)
TBB 0.50a 13.0 1.74 12.5 15.6b 31.2
K44 0.74 34.1 34.4 168 6.90c 9.3
K37 0.25 — — — 1.17 4.7
K25 0.14 1.78 3.30 5.79 3.12 22.3
a Data from [24].
b Data from [30].
c This value may represent an underestimate because, although
50% inhibition is obtained at about 7 mM K44, by increasing the in-
hibitor concentration up to 25 mM inhibition remains at about the
same level.seems to confirm that the shrinkage in the unit cell dimensions ob-
served in previous crystal data was due to the use of high concentra-
tion of dehydrating substances as PEG or glycerol as cryoprotec-
tants.
To find the best position inside the unit cell, an initial rigid body
transformation on the model of the apoenzyme was adequate, using
the CNS software package [51]. The refinement was carried out us-
ing SHELX [52] for K25 and K44 and CNS for K37, for which data at
only 2.3 A˚ resolution were available. The presence of the inhibitor in
the active site was clear since the beginning of the refinement in both
|Fo 2 Fc| and |2Fo 2 Fc| maps for all three compounds. The pres-
ence of high peaks of electron density corresponding to the bromine
atoms made the positioning of the inhibitors straightforward (see
Supplemental Figure S1, available with this article online). The initial
extended electron density for K37 suggested a double orientation
for this inhibitor in the active site, as confirmed by the subsequent
refinement.
The definition files for the inhibitors were initially created by Hic-
Up [53], corrected with the adequate parameters and used in the
whole refinement procedures that was carried out alternating auto-
mated cycles and manual inspection steps using the graphic pro-
gram QUANTA [54]. During the final steps of the refinement, water
molecules, chloride ions (one in K25 and one in K44 complex), and
a DMSO molecule (in K25 complex) were added. The assignment
of peaks in the electron density to chloride ions have been made
on the basis of the intensity of the peaks (more than five sigma)
and the geometry and nature of the coordination ligands around
the peaks (water molecules and nitrogen atoms, at distances be-
tween 3.1 and 3.4 A˚; see Figure 2 for details). A check in the Macro-
molecular Structure Database (www.ebi.ac.uk/msd/index.html)
confirmed that the chlorine ion coordination in our models is in
agreement with the examples reported in the database.
The stereochemistry and geometric properties of the models were
checked with the program PROCHECK [55] and proved to be com-
pletely adequate for the respective resolutions, with no residues in
disallowed regions of the Ramachandran plot. Statistics on final
models are reported in Supplemental Table S1.
Structural Analysis
Calculation of the Accessible Surface Areas (ASA) and their differen-
ces (DASA) have been performed with the program Areaimol from
the CCP4 suite, with a probe of 1.4 A˚ radius and a parameter
PTNDEN = 100 for the best accuracy. The program Contact from
the CCP4 suite has been utilized for the calculation of atom distan-
ces, with two cutoffs of 3.7 and 3.9 A˚, as reported in Table 2.
Supplemental Data
A Supplemental Scheme, Supplemental Table, and Supplemental
Figure are available online at http://www.chembiol.com/cgi/content/
full/12/11/1211/DC1/.
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